DexCom (NASDAQ:DXCM) has been given a $67.00 price objective by analysts at Oppenheimer in a report issued on Monday. The brokerage presently has a “buy” rating on the medical device company’s stock. Oppenheimer’s price target would indicate a potential upside of 22.55% from the stock’s current price. Oppenheimer also issued estimates for DexCom’s Q1 2018 earnings at ($0.32) EPS, Q3 2018 earnings at ($0.04) EPS, Q4 2018 earnings at $0.12 EPS and FY2019 earnings at ($0.06) EPS.

Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Morgan Stanley dropped their price target on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Finally, Northland Securities reissued a “sell” rating and issued a $40.00 price target on shares of DexCom in a research note on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. DexCom has an average rating of “Hold” and an average price target of $67.44.

DexCom (NASDAQ:DXCM) opened at $54.67 on Monday. DexCom has a 12 month low of $42.62 and a 12 month high of $86.32. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $4,750.00, a P/E ratio of -95.91 and a beta of 0.21.

In other news, CEO Kevin R. Sayer sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total transaction of $660,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barbara Kahn sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total value of $163,740.00. Following the transaction, the director now directly owns 4,353 shares in the company, valued at $237,586.74. The disclosure for this sale can be found here. Insiders have sold 48,140 shares of company stock worth $2,743,281 over the last ninety days. 1.70% of the stock is owned by insiders.

Several large investors have recently modified their holdings of DXCM. Prosight Management LP bought a new stake in DexCom during the fourth quarter worth $1,790,000. AXA grew its holdings in DexCom by 44.9% during the fourth quarter. AXA now owns 1,911,206 shares of the medical device company’s stock worth $109,684,000 after buying an additional 592,275 shares in the last quarter. Geode Capital Management LLC grew its holdings in DexCom by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 800,783 shares of the medical device company’s stock worth $45,956,000 after buying an additional 8,444 shares in the last quarter. Amalgamated Bank grew its holdings in DexCom by 5.7% during the fourth quarter. Amalgamated Bank now owns 17,107 shares of the medical device company’s stock worth $982,000 after buying an additional 924 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in DexCom by 6.8% during the fourth quarter. Mackenzie Financial Corp now owns 1,371,595 shares of the medical device company’s stock worth $78,716,000 after buying an additional 87,848 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://theolympiareport.com/2018/02/14/dexcom-dxcm-pt-set-at-67-00-by-oppenheimer.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.